S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   3,294.61 (+0.72%)
DOW   26,664.40 (+0.89%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
Log in

NYSE:VIRVir Biotechnology Stock Price, Forecast & News

$49.52
+1.76 (+3.69 %)
(As of 08/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$46.90
Now: $49.52
$49.85
50-Day Range
$33.55
MA: $43.63
$52.14
52-Week Range
$11.65
Now: $49.52
$75.00
Volume504,945 shs
Average Volume1.19 million shs
Market Capitalization$5.84 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis. The company has grant agreement with Bill & Melinda Gates Foundation and National Institutes of Health; option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; collaboration and license agreement Alnylam Pharmaceuticals, Inc.; collaboration, license and option agreement Visterra, Inc.; and license agreement with The Rockefeller University and MedImmune, Inc. It operates in the United States, Oregon, Massachusetts, and Switzerland. The company was founded in 2016 and is headquartered in San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.66 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone415-906-4324

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees206
Market Cap$5.84 billion
Next Earnings Date8/11/2020 (Confirmed)
OptionableNot Optionable
$49.52
+1.76 (+3.69 %)
(As of 08/3/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VIR News and Ratings via Email

Sign-up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Vir Biotechnology (NYSE:VIR) Frequently Asked Questions

How has Vir Biotechnology's stock been impacted by COVID-19 (Coronavirus)?

Vir Biotechnology's stock was trading at $33.77 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, VIR stock has increased by 46.6% and is now trading at $49.52.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Vir Biotechnology?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vir Biotechnology in the last year. There are currently 2 sell ratings, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Vir Biotechnology
.

When is Vir Biotechnology's next earnings date?

Vir Biotechnology is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020.
View our earnings forecast for Vir Biotechnology
.

How were Vir Biotechnology's earnings last quarter?

Vir Biotechnology (NYSE:VIR) issued its quarterly earnings data on Tuesday, May, 12th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by $0.18. The business had revenue of $5.72 million for the quarter, compared to analyst estimates of $3.21 million.
View Vir Biotechnology's earnings history
.

What price target have analysts set for VIR?

5 analysts have issued twelve-month price objectives for Vir Biotechnology's stock. Their forecasts range from $20.00 to $44.00. On average, they anticipate Vir Biotechnology's stock price to reach $31.75 in the next twelve months. This suggests that the stock has a possible downside of 35.9%.
View analysts' price targets for Vir Biotechnology
.

Has Vir Biotechnology been receiving favorable news coverage?

News headlines about VIR stock have trended somewhat positive on Monday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Vir Biotechnology earned a news impact score of 1.6 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future.
View the latest news about Vir Biotechnology
.

Who are some of Vir Biotechnology's key competitors?

What other stocks do shareholders of Vir Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vir Biotechnology investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Novavax (NVAX), Moderna (MRNA), Johnson & Johnson (JNJ), Micron Technology (MU), Regeneron Pharmaceuticals (REGN), Vaxart (VXRT) and Advanced Micro Devices (AMD).

Who are Vir Biotechnology's key executives?

Vir Biotechnology's management team includes the following people:
  • Dr. George A. Scangos, Pres, CEO & Director (Age 71)
  • Dr. Jay Parrish, Chief Bus. Officer & Co-Founder (Age 44)
  • Dr. Klaus Frueh, Co-Founder & Director (Age 59)
  • Mr. Robert Taylor Nelsen M.B.A., Co-Founder & Director (Age 57)
  • Dr. Lawrence Corey, Co-Founder & Scientific Advisor

When did Vir Biotechnology IPO?

(VIR) raised $149 million in an initial public offering on Friday, October 11th 2019. The company issued 7,100,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays acted as the underwriters for the IPO.

What is Vir Biotechnology's stock symbol?

Vir Biotechnology trades on the New York Stock Exchange (NYSE) under the ticker symbol "VIR."

Who are Vir Biotechnology's major shareholders?

Vir Biotechnology's stock is owned by a number of retail and institutional investors. Top institutional investors include UBS Group AG (0.03%), Anderson Hoagland & Co. (0.03%), Raymond James Financial Services Advisors Inc. (0.03%), SG Americas Securities LLC (0.02%), Northside Capital Management LLC (0.01%) and EPIQ Capital Group LLC (0.01%). Company insiders that own Vir Biotechnology stock include Abu Dhabi Investment Authority, Endurance (Cayman) Ltd Svf, Herbert Virgin, Howard Horn, Jay Parrish, Phillip Pang and Robert J More.
View institutional ownership trends for Vir Biotechnology
.

Which major investors are buying Vir Biotechnology stock?

VIR stock was bought by a variety of institutional investors in the last quarter, including Anderson Hoagland & Co., UBS Group AG, Raymond James Financial Services Advisors Inc., SG Americas Securities LLC, Northside Capital Management LLC, EPIQ Capital Group LLC, Canton Hathaway LLC, and Hoertkorn Richard Charles. Company insiders that have bought Vir Biotechnology stock in the last two years include Abu Dhabi Investment Authority, and Endurance (Cayman) Ltd Svf.
View insider buying and selling activity for Vir Biotechnology
.

How do I buy shares of Vir Biotechnology?

Shares of VIR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Vir Biotechnology's stock price today?

One share of VIR stock can currently be purchased for approximately $49.52.

How big of a company is Vir Biotechnology?

Vir Biotechnology has a market capitalization of $5.84 billion. Vir Biotechnology employs 206 workers across the globe.

What is Vir Biotechnology's official website?

The official website for Vir Biotechnology is www.vir.bio.

How can I contact Vir Biotechnology?

The company can be reached via phone at 415-906-4324.

This page was last updated on 8/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.